Portfolio Management in New Drug Development - Innovation and Marketing in the Pharmaceutical Industry - page 116

Higgins MJ, Rodriguez D (2006) The outsourcing of R&D through acquisitions in the pharmaceu-
tical industry. J Financ Econ 80:351-383
Hitt MA, Hoskisson RE, Duane Ireland R (1990) Mergers and acquisitions and managerial com-
mitment to innovation in M-form firms. Strateg Manag J 11(4):29-47
Hitt MA, Hoskisson RE, Duane Ireland R, Harrison JS (1991) Are acquisitions a poison pill for
innovation? Acad Manag Exec 5(4):22-34
Hutchinson WJ, Alba JW, Eisenstein EM (2010) Heuristics and biases in data-based decision mak-
ing: effects of experience, training, and graphical data displays. J Mark Res 47(4):627-642
IMAP (2011) Pharmaceuticals & Biotech Industry Global Report—2011. http://www.imap.com .
Jaruzelski B, Loehr J, Holman R (2011) The global innovation 1000: why culture is key.
Strategy+Business 65(Winter):31-45
Kauffman S, Lobo J, Macready WG (2000) Optimal search on a technology landscape. J Econ
Behav Organ 43(2):141-166
Kavadias S, Loch CH (2003) Optimal project sequencing with recourse at a scarce resource. Prod
Oper Manag 12(4):433-443
Kuhn D, Luenberger DG (2010) Analysis of the rebalancing frequency in log-optimal portfolio
selection. Quant Finance 10(2):221-234
Lee J (2003) Innovation and strategic divergence: an empirical study of the U. S. pharmaceutical
industry from 1920 to 1960. Manag Sci 49(2):143-159
Lehman DR, Winer RS (2006) Product management. McGraw-Hill, New York
Lintner J (1965) The valuation of risk assets and the selection of risky investments in stock portfo-
lios and capital budgets. Rev Econ Stat 47(1):13-37
Loch CH, Bode-Greuel K (2001) Evaluating growth options as sources of value for pharmaceutical
research projects. R&D Management 31(2):231-248
Loch CH, Kavadias S (2002) Dynamic portfolio selection of NPD programs using marginal
returns. Manag Sci 48(10):1227-1241
Manso G (2011) Motivating innovation. J Finance 66(5):1823-1860
Markowitz H (1952) Portfolio selection. J Finance 7(1):77-91
Moorman C, Miner AS (1998) The convergence of planning and execution: improvisation in new
product development. J Mark 62(3):1-20
Munos B (2009) Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov
8:959-968
Myerson RB (2004) Probability models for economic decisions. Duxbury Press, Pacific Grove, CA
National Institutes of Health (2012) National Center for Advancing Translational Sciences. http://
ncats.nih.gov/ . Accessed Jan 2012
Neyman J, Pearson ES (1933) On the problem of the most efficient tests of statistical hypotheses.
Phil Trans R Soc London A 231(694-706):289-337
Nichols NA (1994) Scientific management at Merck: an interview with CFO Judy Lewent. Harv
Bus Rev 72(1):88-98
Ofek E, Sarvary M (2003) R&D, marketing, and the success of next-generation products. Mark Sci
22(3):355-370
Ofek E, Srinivasan V (2002) How much does the market value an improvement in a product attri-
bute? Mark Sci 21(4):398-411
outsourcing-pharma.com (2003) GSK sets up biopharma research centre. http://www.outsourcing-
pharma.com/Preclinical-Research/GSK-sets-up-biopharma-research-centre . Accessed Sept
2011
Pearson AW (1972) The use of ranking formulae in R & D projects. R&D Management
2(2):69-73
pfizer.com (2011) Pfizer pipeline. http://www.pizer.com/iles/research/pipeline/2011_0811/pipe-
line_2011_0811.pdf . Accessed Sept 2011
PharmaProjects (2010) Pharma R&D annual review 2010. http://www.PharmaProjects.com .
Prabhu JC, Chandy RK, Ellis ME (2005) The impact of acquisitions on innovation: poison pill,
placebo, or tonic? J Mark 69(1):114-130